Dr Jane Sosabowski
My main interests are in radiopharmaceutical development and the use of pre-clinical molecular imaging in drug development, especially biopharmaceuticals.
I am particularly interested in imaging radiolabelled peptides and proteins for use in diagnosis and therapy of cancer. These might be radiolabelled with positron emitters such as 68Ga or 64Cu in order to carry out PET imaging, 111In or 99mTc for SPECT imaging or with therapy radioisotopes such as 90Y and 177Lu. The lab has a long-standing interest in imaging CCK-2 and GRP receptors which are overexpressed in a number of tumour types.
Drug development studies entail using imaging to show specific tissue targeting of small antibodies. The aim is to use these targeting proteins to carry a therapeutic payload to the site of disease and this work is carried out in collaboration with GSK. We also use radioactive probes such as 18F-FDG and 18F-FLT to monitor response to treatment in vivo.
I graduated with a BSc(Hons) in Chemistry from University of Natal, Durban, South Africa and went on carry out an MSc by research into the Photochemistry of Sunscreen Constituents at same university. I then moved to the UK to the Joint Department of Physics at the Institute of Cancer Research in Sutton, Surrey and completed my PhD looking at Development of PET radiotracers for the in vivo assessment of multidrug resistance. I then moved to the Nuclear Medicine Research Laboratory at Barts and the London School of Medicine and Dentistry to carry out a post doc under Prof Stephen Mather. With the advent of pre-clinical imaging systems this lab developed into the Cancer Imaging Laboratory.
- EPSRC PhD CASE studentship
- Industrial collaborations with GSK and inviCRO
- Cancer Research UK
- Barts and the London Charity
- External academic collaborations
Sosabowski, J. K., Matzow, T., Foster, J. M., Finucane, C., Ellison, D., Watson, S. A., and Mather, S. J. (2009) Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide. J Nucl Med 50, 2082-9. PMID: 19910426
Sosabowski, J. K., and Mather, S. J. (2006) Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes. Nature Protocols 1, 972-976. PMID: 17406332
Naqvi, S. A., Matzow, T., Finucane, C., Nagra, S. A., Ishfaq, M. M., Mather, S. J., and Sosabowski, J. (2010) Insertion of a lysosomal enzyme cleavage site into the sequence of a radiolabeled neuropeptide influences cell trafficking in vitro and in vivo. Cancer Biother Radiopharm 25, 89-95. PMID: 20187801
Sosabowski, J. K., Lee, M., Dekker, B. A., Simmons, B. P., Singh, S., Beresford, H., Hagan, S. A., McKenzie, A. J., Mather, S. J., and Watson, S. A. (2007) Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study. Eur J Pharm Sci 31, 102-11. PMID: 17387005
For additional publications, please click here
Cancer Imaging Laboratory
Molecular imaging is an intensely multidisciplinary area of research and the expertise of the laboratory draws from the fields of radiochemistry, animal physiology, imaging science (physics, data analysis), pharmacy, pharmacology and molecular biology. Most studies are carried out by a team of researchers and is intensely collaborative. The Laboratory is extremely well equipped with hot cells for radiolabelling with PET and SPECT radioisotopes, QC equipment (HPLC and TLC analysis) tissue culture facilities for in vitro assays and development of tumour models and gamma and beta counting equipment for ex vivo biodistribution work. Pre-clinical imaging facilities include Siemens Inveon PET/CT and Bioscan NanoSPECT/CT cameras.
- Dr Julie Foster
- Dr Julius Leyton
- Alex Papple - PhD student
- Dr Roxana Kashani Ciara Finucane - Honorary Research Scientist